Ixekizumab is novel drug approved by the FDA for treatment of psoriasis, MOA of this drug is :
Ixekizumab, approved for treatment of plaque psoriasis. It is a humanized IL-17A antagonist that works when IgG4 monoclonal antibodies selectively bind with IL-17A cytokines and inhibit their interaction with the IL-17 receptor. Secukinumab, similar to Ixekizumab, this injectable is an IgG1 monoclonal antibody that selectively binds to the IL-17A cytokine and inhibits its interaction with the IL-17 receptor. It is approved for the treatment of plaque psoriasis and psoriatic ahritis. Ustekinumab : Anti IL-12/23 Apremilast: PDE-4 inhibitor
IL-17A agonist
IL-17A antagonist
IL-12/23 antagonist
PDE 4 inhibitor
Psoriasis